Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapsone 5% gel for Cetuximab-induced acneiform rash
NCT01931150Phase 3Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2013
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapsone in acneiform rash, sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 2013; status: completed.
02
Drugs
dapsone
03
Conditions
acneiform rash
Beyond the preview
Go deeper on NCT01931150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01931150.